TurtleTree Secures FDA No Questions Letter for World's First Precision Fermented Lactoferrin
TurtleTree has received an FDA No Questions Letter for LF+, the world's first precision fermentation-produced lactoferrin, marking a milestone for the company and the industry.
TurtleTree has received an FDA No Questions Letter for LF+, making it the world's first precision fermentation-produced lactoferrin to achieve this regulatory milestone.
What This Means
The FDA No Questions Letter signifies that TurtleTree's self-affirmed GRAS (Generally Recognized as Safe) determination for LF+ has been reviewed by the FDA, and the agency has no further questions regarding its safety for use in food products.
About LF+
LF+ is TurtleTree's flagship product — a sustainably-produced lactoferrin made using precision fermentation technology. It is molecularly identical to bovine lactoferrin but produced without the need for dairy farming.
Market Impact
This regulatory milestone opens the door for LF+ to be commercially available in the United States across multiple product categories, including functional beverages, dietary supplements, sports nutrition, and plant-based foods.